Lidocaïne Hcl Cf

Lidocaine Hydrochloride, the active ingredient in Lidocaïne Hcl Cf, is a local anesthetic presented as a sterile solution for intravenous use. It provides reversible nerve block for minor surgical procedures, ventricular arrhythmias, and diagnostic nerve blocks in adult patients.

GNH USA supplies Lidocaïne Hcl Cf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Lidocaine Hydrochloride is employed in clinical settings that require rapid, reversible nerve blockade.

- Minor surgical procedures: provides local anesthesia to reduce pain during the operation. - Ventricular arrhythmias: stabilizes cardiac rhythm when administered intravenously. - Diagnostic nerve blocks: temporarily blocks nerve conduction for diagnostic testing.

Lidocaine Hydrochloride may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Tingling or numbness at the injection site - Mild dizziness or light‑headedness - Nausea or vomiting - Metallic taste in the mouth - Transient visual disturbances - Headache

Serious or Rare Side Effects: - Severe hypotension or cardiovascular collapse - Life‑threatening cardiac arrhythmias - Anaphylactic or severe allergic reaction - Methemoglobinemia - Central nervous system toxicity (e.g., seizures) - Respiratory depression

Before using Lidocaine Hydrochloride, clinicians should consider several safety measures.

- Allergy assessment: avoid use in patients with known lidocaine hypersensitivity. - Cardiac monitoring: observe patients with pre‑existing heart disease. - Dose adjustment: consider reduced doses in hepatic impairment. - Concurrent CNS depressants: use with caution as additive effects may occur. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at controlled room temperature (15‑30 °C): keep in original container, protect from light and moisture.

Lidocaine Hydrochloride can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine, procainamide): may cause severe cardiotoxicity. - Beta‑blockers (e.g., propranolol): can enhance cardiac depression. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase lidocaine plasma concentrations.

Moderate Interactions (Monitor Closely): - Central nervous system depressants (e.g., benzodiazepines, opioids): additive sedation. - Diuretics (e.g., furosemide): may raise risk of arrhythmias. - Concurrent local anesthetic mixtures: monitor total dose to avoid systemic toxicity.